Emerging therapeutic interventions for idiopathic pulmonary fibrosis

Expert Opinion on Investigational Drugs

Volumn 23, Issue 7, 2014, Pages 893-910

  Chakraborty, Sushmita ^a   Chopra, Puneet ^a   Ambi, Senthil V ^a   Dastidar, Sunanda G ^a   Ray, Abhijit ^a  

^a Daiichi Sankyo India Pharma Pvt Ltd   (India)

Author keywords

Anti fibrotic agents; Apoptosis; Idiopathic pulmonary fibrosis; Inflammation; Pulmonary fibrosis

Indexed keywords

ACETYLCYSTEINE; AMBRISENTAN; ANGIOTENSIN II; BOSENTAN; CARBON MONOXIDE; COLCHICINE; CORTICOSTEROID; ETANERCEPT; EVEROLIMUS; GALECTIN 3; GAMMA INTERFERON; INTERLEUKIN 13; LYSOPHOSPHATIDIC ACID; MACITENTAN; MATRIX METALLOPROTEINASE; MICRORNA; MITOGENIC AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1; PENICILLAMINE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIRFENIDONE; PROTEIN LYSINE 6 OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SOMATOSTATIN; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; APOPTOSIS; CONSTIPATION; DIARRHEA; DIZZINESS; DRY SKIN; FIBROSING ALVEOLITIS; HEADACHE; HUMAN; HYPERPIGMENTATION; INFLAMMATION; NAUSEA; PATHOGENESIS; PHOTOSENSITIVITY; PRURITUS; REVIEW; SIGNAL TRANSDUCTION; WEAKNESS; ANIMAL; IDIOPATHIC PULMONARY FIBROSIS; METABOLISM; PATHOLOGY;

ANIMALS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; SIGNAL TRANSDUCTION;

EID: 84902357335     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.913569     Document Type: Review

References (114)

1. Baumgartner KB, Samet JM, Coultas DB, et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: A multicenter case-control study. Collaborating Centers. Am J Epidemiol 2000;152:307-15 (Pubitemid 30626724
2. Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-42 (Pubitemid 37088595
3. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810-16 (Pubitemid 44511663
4. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:431-40
5. No authors listed American Thoracic Society. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-64
6. Hunninghake GW, Lynch DA, Galvin JR, et al. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest 2003;124:1215-23 (Pubitemid 37290029
7. Flaherty KR, Travis WD, Colby TV, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001;164:1722-7 (Pubitemid 33124165
8. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: Clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157:1301-15
9. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-51 (Pubitemid 32096342
10. Mapel DW, Samet JM, Coultas DB. Corticosteroids and the treatment of idiopathic pulmonary fibrosis: Past, present, and future. Chest 1996;110:1058-67 (Pubitemid 26347626
11. Rafii R, Juarez MM, Albertson TE, Chan AL. A review of current and novel therapies for idiopathic pulmonary fibrosis. J Thorac Dis 2013;5:48-73
12. Piguet PF, Collart MA, Grau GE, et al. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 1989;170:655-63 (Pubitemid 19226654
13. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: An exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008;178:948-55
14. Ross B, D'Orleans-Juste P, Giaid A. Potential role of endothelin-1 in pulmonary fibrosis: From the bench to the clinic. Am J Respir Cell Mol Biol 2010;42:16-20
15. Saleh D, Furukawa K, Tsao MS, et al. Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: Possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol 1997;16:187-93 (Pubitemid 127498240
16. Giaid A, Michel RP, Stewart DJ, et al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosingalveolitis. Lancet 1993;341:1550-4 (Pubitemid 23170459
17. Schroll S, Arzt M, Sebah D, et al. Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan. Respir Physiol Neurobiol 2010;170:32-6
18. Mutsaers SE, Marshall RP, Goldsack NR, et al. Effect of endothelin receptor antagonists (BQ-485, Ro 47- 0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Pulm Pharmacol Ther 1998;11:221-5 (Pubitemid 29041586
19. King TE Jr, Behr J, Brown KK, et al. BUILD-1: A randomized placebocontrolled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;177:75-81
20. Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: A parallel, randomized trial. Ann Intern Med 2013;158:641-9
21. Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: Downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 1995;21:791-08
22. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): A multicentre, randomised, placebocontrolled trial. Lancet 2009;374:222-8
23. Diaz KT, Skaria S, Harris K, et al. Delivery and safety of inhaled interferongamma in idiopathic pulmonary fibrosis. J Aerosol Med Pulm Drug Deliv 2012;25:79-87
24. Malouf MA, Hopkins P, Snell G, Glanville AR; Everolimus in IPF Study Investigators. An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. Respirology 2011;16:776-83
25. Zhang L, Zhu Y, Luo W. The protective effect of colchicine on bleomycininduced pulmonary fibrosis in rats. Chin Med Sci J 1992;7:58-60
26. Peters SG, McDougall JC, Douglas WW, et al. Colchicine in the treatment of pulmonary fibrosis. Chest 1993;103:101-4 (Pubitemid 23027240
27. Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis: A randomized prospective study. Members of the Lung Study Group. Am J Respir Crit Care Med 1998;158:220-5 (Pubitemid 28337184
28. Ward WF, Shih-Heollwarth A, Tuttle RD. Collagen accumulation in irradiated rat lung: Modification by D-penicillamine. Radiology 1983;146:533-7 (Pubitemid 13225505
29. Chapela R, Zuniga G, Selman M. D-penicillamine in the therapy of fibrotic lung diseases. Int J Clin Pharmacol Ther Toxicol 1986;24:16-17 (Pubitemid 16184143
30. Gu?nther A, Lu?bke N, Ermert M, et al. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 2003;168:1358-65 (Pubitemid 37487332
31. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005;128:1475-82 (Pubitemid 41324435
32. Markart P, Nass R, Ruppert C, et al. Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis. J Aerosol Med Pulm Drug Deliv 2010;23:161-72
33. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: A prospective, double-blind randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991;144:291-6
34. Zisman DA, Lynch JPIII, Toews GB, et al. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: A prospective study in patients who failed to respond to corticosteroids. Chest 2000;117:1619-26 (Pubitemid 30413354
35. Alcorn JF, van der Velden J, Brown AL, et al. c-Jun N-terminal kinase 1 is required for the development of pulmonary fibrosis. Am J Respir Cell Mol Biol 2009;40:422-32
36. Hashimoto S, Gon Y, Takeshita I, et al. Transforming growth factor-beta1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-Jun-NH2-terminal kinasedependent pathway. Am J Respir Crit Care Med 2001;163:152-7 (Pubitemid 32095266
37. PlantevinKrenitsky V, Nadolny L, Delgado M, et al. Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg Med Chem Lett 2012;22:1433-8
38. Idiopathic Pulmonary Fibrosis Clinical Research Network. Zisman DA, Schwarz M, Anstrom KJ, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010;363:620-8
39. Wilborn J, Bailie M, Coffey M, et al. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 1996;97:1827-36
40. Peters-Golden M, Bailie M, Marshall T, et al. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 2002;165:229-35 (Pubitemid 34084463
41. Failla M, Genovese T, Mazzon E, et al. Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. Respir Res 2006;7:137
42. Leask A, Abraham DJ. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol 2003;81:355-63 (Pubitemid 38186975
43. Bonniaud P, Martin G, Margetts PJ, et al. Connective tissue growth factor is crucial to inducing a profibrotic environment in "fibrosis- resistant" BALB/c mouse lungs. Am J Respir Cell Mol Biol 2004;31:510-16
44. Allen JT, Knight RA, Bloor CA, Spiteri MA. Enhanced insulin-like growth factor binding protein-related protein 2 (Connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1999;6:693-700 (Pubitemid 129502288
45. Wang Q, Usinger W, Nichols B, et al. Cooperative interaction of CTGF and TGF-b in animal models of fibrotic disease. Fibrogenesis Tissue Repair 2011;4(1):4
46. Koch HP. Thalidomide and congeners as anti-inflammatory agents. Prog Med Chem 1985;22:165-42
47. Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993;177:1675-80 (Pubitemid 23146134
48. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5 (Pubitemid 24139577
49. Tabata C, Tabata R, Kadokawa Y, et al. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J Immunol 2007;179:708-14 (Pubitemid 46986590
50. Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: A randomized trial. Ann Intern Med 2012;157:398-06
51. Oriente A, Fedarko NS, Pacocha SE, et al. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 2000;292:988-94 (Pubitemid 30136592
52. Saito A, Okazaki H, Sugawara I, et al. Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro. Int Arch Allergy Immunol 2003;132:168-76 (Pubitemid 37409848
53. Borowski A, Kuepper M, Horn U, et al. Interleukin-13 acts as an apoptotic effector on lung epithelial cells and induces pro-fibrotic gene expression in lung fibroblasts. Clin Exp Allergy 2008;38:619-28 (Pubitemid 351406073
54. Hancock A, Armstrong L, Gama R, Millar A. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 1998;18:60-5 (Pubitemid 128355347
55. Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999;103:779-88 (Pubitemid 29152623
56. Kolodsick JE, Toews GB, Jakubzick C, et al. Protection from fluorescein isothiocyanate-induced fibrosis in IL-13- deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J Immunol 2004;172:4068-76 (Pubitemid 38375218
57. Belperio JA, Dy M, Burdick MD, et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am JRespir Cell Mol Biol 2002;27:419-27
58. Lebtahi R, Moreau S, Marchand-Adam S, et al. Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis. J Nucl Med 2006;47:1281-7 (Pubitemid 47544880
59. Reynaert H, Rombouts K, Jia Y, et al. Somatostatin at nanomolar concentration reduces collagen I and III synthesis by, but not proliferation of activated rat hepatic stellate cells. Br J Pharmacol 2005;146:77-88 (Pubitemid 43086097
60. Wang J, Zheng H, Hauer-Jensen M. Influence of Short-Term Octreotide Administration on Chronic Tissue Injury, Transforming Growth Factor beta (TGF-beta) Overexpression, and Collagen Accumulation in Irradiated Rat Intestine. J Pharmacol Exp Ther 2001;297:35-42 (Pubitemid 32242560
61. Valatas V, Kolios G, Manousou P, et al. Octreotide regulates CC but not CXC LPS-induced chemokine secretion in rat Kupffer cells. Br J Pharmacol 2004;141:477-87 (Pubitemid 38297010
62. Borie R, Fabre A, Prost F, et al. Activation of somatostatin receptors attenuates pulmonary fibrosis. Thorax 2008;63:251-8 (Pubitemid 351373721
63. Crestani B, Chapron J, Wallaert B, et al. Octreotide treatment of idiopathic pulmonary fibrosis: A proof-of-concept study. Eur Respir J 2012;39:772-5
64. Tager AM, LaCamera P, Shea BS, et al. The Lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008;14:45-54
65. Ley K, Zarbock A. From lung injury to fibrosis. Nat Med 2008;14:20-2
66. Kagan HM, Li W. Lysyl oxidase: Properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 2003;88:660-72 (Pubitemid 36258816
67. Boak AM, Roy R, Berk J, et al. Regulation of lysyl oxidase expression in lung fibroblasts by transforming growth factor-b1 and prostaglandin E2. Am J Respir Cell Mol Biol 1994;11:751-5
68. Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010;16:1009-17
69. Azuma A. Pirfenidone: Antifibrotic agent for idiopathic pulmonary fibrosis. Expert Rev Resp Med 2010;4:301-10
70. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-7 (Pubitemid 40616955
71. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone clinical study group in Japan. Pirfenidone in idiopathic pulmonary fibrosis: A phase III clinical trial in Japan. Eur Respir J 2010;35:821-9
72. Azuma A, Taguchi Y, Ogura T, Pirfenidone Clinical Study Group in Japan. Exploratory analysis of a Phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 2011;12:143
73. Atkuri KR, Mantovani JJ, Herzenberg LA. N-Acetylcysteine-A safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 2007;7:355-9 (Pubitemid 47289259
74. Behr J, Maier K, Degenkolb B, et al. Antioxidative and clinical effects of highdose n-Acetylcysteine in fibrosingalveolitis: Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997;156:1897-01
75. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-42 (Pubitemid 41697286
76. Sime PJ, Xing Z, Graham FL, et al. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997;100:768-76 (Pubitemid 27371693
77. Kelly M, Kolb M, Bonniaud P, Gauldie J. A re-evaluation of fibrogenic cytokines in lung fibrosis. Curr Pharm Des 2003;9:39-49 (Pubitemid 36131704
78. Bonniaud P, Margetts PJ, Kolb M, et al. Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med 2005;171:889-98 (Pubitemid 40562720
79. Higashiyama H, Yoshimoto D, Kaise T, et al. Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. Exp Mol Pathol 2007;83:39-46 (Pubitemid 46842964
80. Horan GS, Wood S, Ona V, et al. Partial inhibition of integrin alpha(v) beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 2008;177:56-65
81. Amara N, Goven D, Prost F, et al. NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts. Thorax 2010;65:733-8
82. Laleu B, Gaggini F, Orchard M, et al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem 2010;53:7715-30
83. Chilosi M, Poletti V, Zamò A, et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003;162:1495-02
84. Yi ES, Williams ST, Lee H, et al. Keratinocyte growth factor ameliorates radiation- And bleomycin-induced lung injury and mortality. Am J Pathol 1996;149:1963-70 (Pubitemid 26415215
85. Aguilar S, Scotton CJ, McNulty K, et al. Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS ONE 2009;4:e8013
86. Chakraborty S, Chopra P, Hak A, et al. Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis. Expert Opin Investig Drugs 2013;22:499-515
87. Marshall RP, Gohlke P, Chambers RC, et al. Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol 2004;286:L156-64
88. Wang R, Ibarra-Sunga O, Verlinski L, et al. Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol 2000;279:L143-51
89. Otterbein LE, Mantell LL, Choi AM. Carbon monoxide provides protection against hyperoxic lung injury. Am J Physiol 1999;276:L688-94
90. Song R, Kubo M, Morse D, et al. Carbon monoxide induces cytoprotection in rat orthotopic lung transplantation via anti-inflammatory and anti-Apoptotic effects. Am J Pathol 2003;163:231-42 (Pubitemid 36759607
91. Chapman JT, Otterbein LE, Elias JA, Choi AM. Carbon monoxide attenuates aeroallergen-induced inflammation in mice. Am J Physiol 2001;281:L209-16
92. Otterbein LE, Bach FH, Alam J, et al. Carbon monoxide has anti-inflammatory effects involving the mitogen-Activated protein kinase pathway. Nat Med 2000;6:422-8 (Pubitemid 30208159
93. Zhou Z, Song R, Fattman CL, et al. Carbon monoxide suppresses bleomycininduced lung fibrosis. Am J Pathol 2005;166:27-37 (Pubitemid 40051657
94. Adamali HI, Maher TM. Current and novel drug therapies for idiopathicpulmonary fibrosis. Drug Des Devel Ther 2012;6:261-72
95. Keane MP, Belperio JA, Burdick MD, et al. ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001;164:2239-42 (Pubitemid 34032941
96. Burdick MD, Murray LA, Keane MP, et al. CXCL11 attenuates bleomycininduced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med 2005;171:261-8
97. Brewer GJ, Dick R, Ullenbruch MR, et al. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J Inorg Biochem 2004;98:2160-7 (Pubitemid 39488145
98. Wang X, Zhu H, Yang X, et al. Vasohibin attenuates bleomycin induced pulmonary fibrosis via inhibition of angiogenesis in mice. Pathology 2010;42:457-62
99. Wan YY, Tian GY, Guo HS, et al. Endostatin, an angiogenesis inhibitor, ameliorates bleomycin-induced pulmonary fibrosis in rats. Respir Res 2013;14:56
100. Pardo A, Selman M. Role of matrix metaloproteases in idiopathic pulmonary fibrosis. Fibrogenesis Tissue Repair 2012;5:S9
101. Fujita M, Ye Q, Ouchi H, et al. Doxycycline attenuated pulmonary fibrosis induced by bleomycin in mice. Antimicrob Agents Chemother 2006;50:739-43 (Pubitemid 43190990
102. Bhattacharyya P, Nag S, Bardhan S, et al. The role of long-term doxycycline in patients of idiopathic pulmonaryfibrosis: The results of an open prospective trial. Lung India 2009;26:81-5
103. Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-b1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 2012;185:537-46
104. Allen JT, Spiteri MA. Growth factors in idiopathic pulmonary fibrosis: Relative roles. Respir Res 2002;3:13
105. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-82
106. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079-87
107. Antoniades HN, Bravo MA, Avila RE, et al. Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest 1990;86:1055-64 (Pubitemid 20370408
108. Daniels CE, Wilkes MC, Edens M, et al. Imatinibmesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004;114:1308-16 (Pubitemid 40385302
109. Daniels CE, Lasky JA, Limper AH, et al. Imatinib-IPF Study Investigators.Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010;181:604-10
110. Vittal R, Fisher A, Gu H, et al. Peptide-mediated inhibition of mitogenactivated proteinkinase-Activated protein kinase-2 ameliorates bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2013;49:47-57
111. Conte E, Gili E, Fruciano M, et al. PI3K p110gamma overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: In vitro effects of its inhibition. Lab Invest 2013;93:566-76
112. Wei X, Han J, Chen ZZ, et al. A phosphoinositide 3-kinase-gamma inhibitor, AS605240 prevents bleomycininduced pulmonary fibrosis in rats. Biochem Biophys Res Commun 2010;397:311-17
113. Russo RC, Garcia CC, Barcelos LS, et al. Phosphoinositide 3-kinase g plays a critical role in bleomycin-induced pulmonary inflammation and fibrosis in mice. J Leukoc Biol 2011;89:269-82
114. Scotton CJ, Chambers RC. Bleomycin revisited: Towards a more representative model of IPF? Am J Physiol Lung Cell Mol Physiol 2010;299:L439-41.